PRELIMINARY CLINICAL RESULTS IN THE USE OF PERFLUOROCHEMICALS AS ULTRASOUND CONTRAST AGENTS FOR TUMOR AND HEPATOSPLENOGRAPHY.

Robert F. Mattrey, G. Strich, B. Gosink, G. Beopold, T. Lee, N. McIntosh, C. Wisdom

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Ultrasound contrast agents are currently limited to the transient enhancement of the intravascular space following the injection of microbubbles. It is shown that perfluorocarbon emulsions (PFC's), unlike microbubbles, produce persistent echogenic enhancement of the liver, spleen and VX2 tumors. Tumor enhancement was secondary to the intense accumulation of PFC-filled macrophages at the tumor periphery. The purposes of the current study were to assess the effect of Fluosol DA 20%, a PFC given intravenously to patients, on the acoustic properties of the liver, spleen, and liver lesions and to determine the optimum effective dose. Fluosol given to two patients at 4 ml/kg produced no detectable effect. Three patients, one with colon and two with pancreatic carcinoma, given 8 ml/kg showed no detectable hepatic or splenic enhancement. However, in all 3 patients, changes in the echogenicity of the liver lesions occurred.

Original languageEnglish (US)
Title of host publicationProceedings of the Annual Meeting of the American Institute of Ultrasound in Medicine
PublisherAmerican Inst of Ultrasound in Medicine (Suppl to Journal of Ultrasound in Medicine v 3 n 9 Sep 1984)
Number of pages1
StatePublished - Dec 1 1984

ASJC Scopus subject areas

  • General Engineering

Fingerprint

Dive into the research topics of 'PRELIMINARY CLINICAL RESULTS IN THE USE OF PERFLUOROCHEMICALS AS ULTRASOUND CONTRAST AGENTS FOR TUMOR AND HEPATOSPLENOGRAPHY.'. Together they form a unique fingerprint.

Cite this